Where does Shahzad Malik work?

Shahzad Malik is General Partner at Advent Life Sciences and Board director at Acutus Medical and Board director at Moximed and Board director at Agenus.

What does Shahzad Malik invest in?

Shahzad Malik invests in Biotech.

What check size does Shahzad Malik write?

Shahzad Malik typically writes checks of $25K – $5M.

What boards does Shahzad Malik sit on?

Shahzad Malik holds tracked board seats at Curve Therapeutics, Moximed, Moximed, Orphalan, Proximie.

Where did Shahzad Malik go to school?

Shahzad Malik studied at University of Cambridge (MB,BChir, Medicine); University of Oxford (MA, Medicine).

Shahzad Malik

Investor

General Partner at Advent Life Sciences · Board director at Acutus Medical · Board director at Moximed · Board director at Agenus

London

Writes $25K – $5M checks · typically $1M

Find your path to Shahzad

544 people in our graph share verified history with Shahzad — schools, employers, funds. One of them is your warm intro.

Stephane KurganunlockedShahzad: together at McKinsey & Company (1997–1999)

×9Shahzad: together at McKinsey & Company

Shahzad: together at University of Cambridge

Shahzad: together at NHS

About

Shahzad Malik joined Advent in 1999 with a background in science, clinical medicine, and international finance. He holds an MA in Physiological Sciences from Oxford University and an MD from Cambridge University, and previously specialised in interventional cardiology while conducting research on heart muscle disorders. At Advent he has worked with over 30 life sciences portfolio companies across Europe and the USA.

Contact· self-published, not guessed

s•••@adventls.comreveal

Invests in

Biotech

Board director at Acutus Medical

Intro paths

→

In turn, Shahzad can intro founders to Acutus Medical's investors below.

Acutus Medical's investors · 6

Advent Life SciencesLondon Deerfield Management CompanyNew York · since 2022 Formation GroupLos Altos · since 2019 GE VenturesCincinnati Index VenturesSan Francisco · $540K – $10.8M checks OrbiMedNew York · $1M – $75M checks · since 2022

Co-founders at Acutus Medical

Christoph ScharfDirector

Randy WernethExecutive Officer, Director

Graydon BeattyExecutive Officer

Board director at Moximed

Intro paths

→

In turn, Shahzad can intro founders to Moximed's investors below.

Moximed's investors · 8

Advent Life SciencesLondon · since 2024 Future FundLondon GBS Venture Partners Ltd.Melbourne · $165K – $7.9M checks Gilde HealthcareUtrecht · $1.1M – $55M checks Lightstone VenturesPortola Valley New Enterprise Associates (NEA)Menlo Park · $200K – $40M checks · since 2024 Runway Growth CapitalMenlo Park · $10M – $150M checks Vertex Ventures HCSingapore · $500K – $10M checks

Board director at Agenus

Intro paths

→

In turn, Shahzad can intro founders to Agenus's investors below.

Agenus's investors · 9

Advent Life SciencesLondon Commodore CapitalNew York · since 2026 Grazia Equity GmbHStuttgart · $540K – $2.7M checks HEALTHCARE ROYALTY PARTNERSNew York InvusNew York · since 2026 Ligand PharmaceuticalsJupiter · $10M – $50M checks · since 2026 National Institutes of Health (NIH)since 2016 Oberland CapitalNew York · $50M – $300M checks RA CapitalBoston · since 2026

Co-founders at Agenus

Garo ArmenChairman & CEO, Co-founder

Experience

Advent Life Sciences LLPGeneral Partnercurrent1999 — present
MQ: Transforming Mental HealthChair Of The Board Of Trusteescurrent2019 — present
McKinsey & CompanyAssociate1997 — 1999
NHSInterventional Cardiologist1991 — 1997

Skills & more

Venture Capital61Private Equity17Start-ups23Growth Capital33Entrepreneurship12Mergers3Corporate Development31Lifesciences10Biotechnology12Valuation8Commercialization7Investor Relations7

+12 more

Emerging MarketsIPOMedical DevicesBoard of DirectorsJoint VenturesCapital RaisingAngel InvestingDeal SourcingStrategyBusiness DevelopmentIntellectual PropertyDue Diligence

From Shahzad's professional profile.

Deals · 1

MoximedBoard seat

via Advent Life Sciences · filed Aug 2024 · $91M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

Curve TherapeuticsOrphalan Proximie

Investor

AlgetaAxonics Modulation TechnologiesBiocartisCardiAQMicrometMiroBioRespivert

Sources: the firm's website · SEC Form D filings.

Colleagues at Advent Life Sciences

Alain Huriez

Venture Partner at Advent Life Sciences

Alan Walts

Venture Partner at Advent Life Sciences

Andrea Beesley

Team Assistant at Advent Life Sciences

Bonita Theara

Executive Assistant at Advent Life Sciences

Dale Pfost

Executive Officer at Advent Life Sciences

Dominic Schmidt

General Partner at Advent Life Sciences

Don Drakeman

Distinguished Research Professor, biotech entrepreneur, and venture partner

Fraser Murray

Head of Scientific Evaluation at Advent Life Sciences

Frequently asked questions

Who is Shahzad Malik?: Shahzad Malik joined Advent in 1999 with a background in science, clinical medicine, and international finance. He holds an MA in Physiological Sciences from Oxford University and an MD from Cambridge University, and previously specialised in interventional cardiology while conducting research on heart muscle disorders. At Advent he has worked with over 30 life sciences portfolio companies across Europe and the USA.
Where does Shahzad Malik work?: Shahzad Malik is General Partner at Advent Life Sciences and Board director at Acutus Medical and Board director at Moximed and Board director at Agenus.
What does Shahzad Malik invest in?: Shahzad Malik invests in Biotech.
What check size does Shahzad Malik write?: Shahzad Malik typically writes checks of $25K – $5M.
What boards does Shahzad Malik sit on?: Shahzad Malik holds tracked board seats at Curve Therapeutics, Moximed, Moximed, Orphalan, Proximie.
What companies has Shahzad Malik invested in?: Investments tracked here include Algeta, Axonics Modulation Technologies, Biocartis, CardiAQ, Micromet, MiroBio, Respivert.
Where did Shahzad Malik go to school?: Shahzad Malik studied at University of Cambridge (MB,BChir, Medicine); University of Oxford (MA, Medicine).